Formatech fills for Phase I Cellceutix study

Drug formulator Formatech of Andover, MA, will prep Kevetrin, a candidate for the treatment of drug-resistant cancers, for a Cellceutix Phase I study. The small-molecule substance will take the form of a lyophilized powder for reconstitution in saline solution. Terms were not disclosed. Formatech also runs the Fillanthropy program, through which Tracon Pharma recently received an aseptic fill and finish donation for one lot of its TRC102 cancer treatment candidate. Cellceutix release | Tracon announcement

Suggested Articles

A biotech that worked with a nutritional products maker on the API for its clinical-stage radiation drug, is buying all of the manufacturing know-how.

Merck KGaA is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on newer meds.

In a first, the FDA and Indian oversight agencies worked together to block illegal drugs from entering the U.S.